SCOTUS Rules on Abortion Pill Mifepristone

In a highly anticipated decision, the Supreme Court has unanimously rejected a challenge to the FDA’s approval of mifepristone, a drug used in medication abortions. The ruling preserves access to the pill nationwide. The plaintiffs, a group of doctors and medical associations, argued that the FDA’s expansion of access to mifepristone was unsafe and caused them harm. The court found that the plaintiffs lacked standing to bring the case, meaning they did not demonstrate a sufficient injury to justify a lawsuit. This decision leaves the current FDA regulations in place, allowing mifepristone to be prescribed via telehealth and mailed to patients in states where abortion is legal.

Justice Kavanaugh delivered the opinion, emphasizing that the plaintiffs’ concerns should be addressed through the political and regulatory process, not the courts. This ruling is a significant victory for abortion rights advocates. The legal battle over abortion access is far from over, as state-level restrictions and challenges to other abortion laws continue to be litigated across the country.